Results 21 to 30 of about 7,344,469 (193)

Immunopharmacological approach of carvedilol in chronic Chagas heart disease. [PDF]

open access: yesArq Bras Cardiol, 2014
Dear Editor, Evidence suggests that approximately 12 million individuals in Latin America are infected with Trypanosoma cruzi and present Chagas disease1. Even though the disease was described more than 100 years ago, chemotherapy directed against its etiological agent is restricted to two compounds which are only effective in the acute phase of the
Miranda CP, Botoni FA, Rocha MO.
europepmc   +5 more sources

Endomyocardial biopsy in Chagas' heart disease: pathogenetic contributions

open access: yesSão Paulo Medical Journal
Endomyocardial biopsy procedure has been performed in many centers around the world, allowing a better treatment and follow up of the patients with myocardial disease.
Maria de Lourdes Higuchi
doaj   +2 more sources

Pathogenesis of Chronic Chagas Heart Disease [PDF]

open access: yesCirculation, 2007
Background— Chagas disease remains a significant public health issue and a major cause of morbidity and mortality in Latin America. Despite nearly 1 century of research, the pathogenesis of chronic Chagas cardiomyopathy is incompletely understood, the most intriguing challenge of which is the complex
Jose Antonio, Marin-Neto   +3 more
openaire   +2 more sources

Different infective forms trigger distinct immune response in experimental Chagas disease. [PDF]

open access: yes, 2012
Although metacyclic and blood trypomastigotes are completely functional in relation to parasite-host interaction and/or target cell invasion, they differ in the molecules present on the surface.
Olindo Assis Martins-Filho   +35 more
core   +2 more sources

Epicardial ablation for ventricular tachycardia in chronic Chagas heart disease. [PDF]

open access: yesArq Bras Cardiol, 2014
The Chagas Heart Disease, described for the first time in 1909 by Carlos Chagas, is caused by Trypanosoma cruzi, a flagellated protozoa transmitted to humans, mostly by the feces of Triatoma infestans in endemic areas. Estimates are that fifteen million people are infected in Latin America, leading to 45,000 deaths per year, 90% owing to heart disease.
Scanavacca M.
europepmc   +5 more sources

Chagas Disease and Heart Failure: An Expanding Issue Worldwide [PDF]

open access: yes, 2019
Chagas disease, originally a South American endemic health problem, is expanding worldwide because of people migration. Its main impact is on the cardiovascular system, producing myocardial damage that frequently results in heart failure.
Eduardo Perna   +3 more
core   +1 more source

Mitochondrial DNA Haplogroups and Variants Predispose to Chagas Disease Cardiomyopathy

open access: yesHearts, 2023
Cardiomyopathies are major causes of heart failure. Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central and South America.
Frédéric Gallardo   +39 more
doaj   +1 more source

4.1 PILOT STUDY ON THE PRECLINICAL VASCULAR DAMAGE IN BOLIVIAN PATIENTS WITH CHAGAS INDETERMINATE CHRONIC PHASE

open access: yesArtery Research, 2017
Background: In Italy, the prevalence of seropositivity for Trypanosoma cruzi in immigrants from endemic countries is about 11.3% (30.7% for Bolivian immigrants).
Filippo Valbusa   +7 more
doaj   +1 more source

Enhancing patient care: a multimodality strategy for dilated cardiomyopathy in Chagas disease [PDF]

open access: yesExploration of Cardiology
Chagas disease is a systemic illness characterized by acute and chronic phases. If untreated, it can lead to dysfunction of vital organs, notably the heart, ultimately resulting in heart failure.
Luigy Vasquez-Yeng   +8 more
doaj   +1 more source

Increased aortic stiffness in adults with chronic indeterminate Chagas disease.

open access: yesPLoS ONE, 2019
An ever-increasing number of patients with chronic indeterminate Chagas disease are diagnosed with early vascular and cardiac abnormalities, as cardiovascular imaging becomes more sensitive.
Filippo Valbusa   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy